Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc.verified

RANI

Price:

$2.41

Market Cap:

$135.94M

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatm...[Read more]

Industry

Biotechnology

IPO Date

2021-07-30

Stock Exchange

NASDAQ

Ticker

RANI

The Enterprise Value as of November 2024 (TTM) for Rani Therapeutics Holdings, Inc. (RANI) is 166.17M

According to Rani Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 166.17M. This represents a change of 54.28% compared to the average of 107.71M of the last 4 quarters.

Rani Therapeutics Holdings, Inc. (RANI) Historical Enterprise Value (quarterly & annually)

How has RANI Enterprise Value performed in the past?

The mean historical Enterprise Value of Rani Therapeutics Holdings, Inc. over the last ten years is 184.18M. The current 166.17M Enterprise Value has changed 8.92% with respect to the historical average. Over the past ten years (40 quarters), RANI's Enterprise Value was at its highest in in the June 2021 quarter at 515.79B. The Enterprise Value was at its lowest in in the March 2020 quarter at 0.

Quarterly (TTM)
Annual

Average

184.18M

Median

147.84M

Minimum

108.41M

Maximum

316.09M

Rani Therapeutics Holdings, Inc. (RANI) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Rani Therapeutics Holdings, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 38.56%

Maximum Annual Enterprise Value = 316.09M

Minimum Annual Increase = -53.23%

Minimum Annual Enterprise Value = 108.41M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
2023108.41M-24.57%
2022143.73M-29.83%
2021204.84M38.56%
2020147.84M-53.23%

Rani Therapeutics Holdings, Inc. (RANI) Average Enterprise Value

How has RANI Enterprise Value performed in the past?

The current Enterprise Value of Rani Therapeutics Holdings, Inc. (RANI) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

152.33M

5-year avg

184.18M

10-year avg

184.18M

Rani Therapeutics Holdings, Inc. (RANI) Enterprise Value vs. Peers

How is RANI’s Enterprise Value compared to its peers?

Rani Therapeutics Holdings, Inc.’s Enterprise Value is greater than Vincerx Pharma, Inc. (4.98M), greater than Tenaya Therapeutics, Inc. (147.56M), less than Corvus Pharmaceuticals, Inc. (550.07M), greater than ALX Oncology Holdings Inc. (80.42M), greater than Lyra Therapeutics, Inc. (22.05M), less than Trevi Therapeutics, Inc. (208.91M), greater than SQZ Biotechnologies Company (24.11M), greater than Protara Therapeutics, Inc. (-31165818.00), greater than TRACON Pharmaceuticals, Inc. (-6133696.00), greater than Vaccinex, Inc. (8.95M), greater than Monopar Therapeutics Inc. (81.10M), greater than Miromatrix Medical Inc. (90.06M), greater than Surrozen, Inc. (2.49M), less than Monte Rosa Therapeutics, Inc. (478.04M), greater than PMV Pharmaceuticals, Inc. (48.13M), less than Pharvaris N.V. (844.47M), less than Tyra Biosciences, Inc. (772.84M), greater than Molecular Partners AG (57.66M), greater than Cabaletta Bio, Inc. (24.18M), greater than Viracta Therapeutics, Inc. (12.72M), less than EyePoint Pharmaceuticals, Inc. (707.60M), less than Biomea Fusion, Inc. (241.97M),

Build a custom stock screener for Rani Therapeutics Holdings, Inc. (RANI) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rani Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Rani Therapeutics Holdings, Inc. (RANI) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Rani Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Rani Therapeutics Holdings, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI)?

What is the 3-year average Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI)?

What is the 5-year average Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI)?

How does the current Enterprise Value for Rani Therapeutics Holdings, Inc. (RANI) compare to its historical average?